ホーム › 血液がん › ニューヨーク › New York City
New York City、NYにおける血液がんの臨床試験
New York Cityとその周辺地域（約30マイル以内）の拠点で、血液がんに関する26件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
被験者募集中第1相
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- NYP/Weill Cornell Medical Center, New York
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
被験者募集中第3相
- Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 0032), New York
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
被験者募集中観察研究健康なボランティア歓迎
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
被験者募集中第1相
- NYU Langone Health, New York
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
被験者募集中第2相
- Mount Sinai Medical Center, New York
Genomic Profiling in Cancer Patients
被験者募集中観察研究
- Metropolitan Hospital Center, New York
- Ralph Lauren Center for Cancer Care and Prevention, New York
- Memorial Sloan Kettering Cancer Center, New York
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
被験者募集中第3相
- David H. Koch Center for Cancer Care, New York
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
被験者募集中第1相
- Memorial Sloan Kettering Cancer Center, New York
A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies
被験者募集中第1/2相
- Research Site, New York
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
被験者募集中第3相
- Icahn School of Medicine at Mount Sinai, New York
- Columbia University, New York
- Weill Cornell Medical Center, New York
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
被験者募集中第1相
- Memorial Sloan Kettering Cancer Center, New York
- Weill Cornell Medical College-NY Presbyterian Hospital, New York
Mobile Health Application (PACT) to Improve Engagement in Advance Care Planning
被験者募集中健康なボランティア歓迎
- NYP/Weill Cornell Medical Center, New York
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
被験者募集中第2相
- Weill Cornell Medicine - New York Presbyterian Hospital, New York
A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant
被験者募集中第2相
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
被験者募集中観察研究
- New York University Langone Medical Center, New York
- New York Presbyterian Hospital at Cornell, New York
- Mount Sinai Medical Center - New York, New York
- 他3件
A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant
被験者募集中第2相
- New York University (Data Collection Only), New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
IVIG for Infection Prevention After CAR-T-Cell Therapy
被験者募集中第2相
- Memorial Sloan Kettering Cancer Center, New York
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
被験者募集中第3相
- New York Presbyterian Hospital, New York
- Mt Sinai Medical Center, New York
Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers
被験者募集中観察研究
- Mount Sinai Hospital, New York
- Memorial Sloan Kettering Cancer Center, New York
A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties
被験者募集中健康なボランティア歓迎
- Memorial Sloan Kettering Cancer Center (All protocol activities), New York
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
被験者募集中第1/2相
- Mt Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
被験者募集中第1相
- New York - Presbyterian / Weill Cornell Medicine, New York
- Mount Sinai - Ruttenberg Treatment Center, New York
- Columbia University Medical Center, New York
MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)
被験者募集中観察研究
- Memorial Sloan Kettering Cancer Center, New York
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
被験者募集中第1相
- Memorial Sloan Kettering Cancer Center, New York
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
被験者募集中第1相
- Children's Hospital New York-Presbyterian, New York
- Memorial Sloan Kettering Cancer Center, New York
Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT
被験者募集中第1/2相
- Memorial Sloan Kettering Cancer Center (MSKCC), New York
他の都市における血液がんの試験
- Houston, TX46件の研究
- Boston, MA25件の研究
- Washington, DC19件の研究
- Seattle, WA18件の研究
- Baltimore, MD18件の研究
- Los Angeles, CA17件の研究
- Durham, NC16件の研究
- Chicago, IL15件の研究
- Philadelphia, PA14件の研究
- Nashville, TN13件の研究
- Columbus, OH13件の研究
- Edison, NJ13件の研究
New York Cityにおける他の研究
- 乳がん136件の研究
- 非小細胞肺癌121件の研究
- がん（全種類）109件の研究
- 前立腺がん103件の研究
- 転移性癌93件の研究
- 大腸癌78件の研究
- 卵巣がん69件の研究
- 肺がん60件の研究
- 多発性骨髄腫60件の研究
- 膵臓がん60件の研究
- 子宮内膜がん52件の研究
- 急性骨髄性白血病51件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。